We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
- Authors
Morris, Tessa A.; Khoo, Christine; Solomon, Benjamin J.
- Abstract
ROS1 gene rearrangements exist in 1–2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine kinase inhibitor to demonstrate activity in ROS1-rearranged lung cancer, and remains the recommended first-line therapy for patients with advanced ROS1-rearranged non-small cell lung cancer. Despite excellent initial responses to crizotinib, the majority of patients develop disease progression, which may be intracranial or extracranial. Identification of resistance mechanisms to crizotinib, and newer generation tyrosine kinase inhibitors with increased potency against ROS1 and ROS1-resistance mutations, and improved intracranial activity are under evaluation in clinical trials. In this review, we discuss ROS1 rearrangements in non-small cell lung cancer, and provide an update on targeting ROS1-rearranged non-small cell lung cancer with crizotinib and newer generation tyrosine kinase inhibitors.
- Subjects
PROTEIN-tyrosine kinase inhibitors; DRUG resistance; GENE expression; LUNG cancer; GENETIC mutation; DISEASE progression; PIPERIDINE; PHARMACODYNAMICS; THERAPEUTICS
- Publication
Drugs, 2019, Vol 79, Issue 12, p1277
- ISSN
0012-6667
- Publication type
Article
- DOI
10.1007/s40265-019-01164-3